Latest News and Press Releases

Tekjur fyrstu níu mánuði ársins voru 8,7 milljarðar króna samanborið við 291 milljón króna á sama tímabili í fyrraViðræður héldu áfram við Bandaríska lyfjaeftirlitið (FDA) um meðferð beggja umsókna um...

Increases availability of cost-effective high-concentration low-volume adalimumab in AustraliaFirst approved biosimilar from the partnership with Cipla, which also includes four other biosimilar...

Increases availability of cost-effective high-concentration low-volume adalimumab in AustraliaFirst approved biosimilar from the partnership with Cipla, which also includes four other biosimilar...

Eykur aðgengi að hagkvæmu adalimumab í háum styrk í ÁstralíuFyrsta líftæknilyfjahliðstæðan í samstarfi Alvotech og Cipla, en fyrirtækin vinna einnig saman að fjórum öðrum verkefnum Alvotech (First...

Alvotech will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02The switching study was conducted to investigate the pharmacokinetics, immunogenicity,...

Alvotech will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02The switching study was conducted to investigate the pharmacokinetics,...

Alvotech mun halda þrjár kynningar sem tengjast rannsókn á útskiptileika AVT02Rannsóknin var gerð til að kanna lyfjahvörf, klíníska virkni, öryggi og þolanleika í sjúklingum sem skiptu endurtekið á...

REYKJAVIK, Iceland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...

Alvotech mun birta uppgjör fyrir fyrstu níu mánuði ársins 2022, eftir lokun markaða í Bandaríkjunum þriðjudaginn 15. nóvember n.k. Kynningarfundur fyrir markaðsaðila verður haldinn í beinu streymi...